Opening Pandora’s Pillbox: Using Modern Information Tools To Improve Drug Safety
- 1 July 2005
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 24 (4) , 938-948
Abstract
How the Food and Drug Administration (FDA) responds to criticism of its drug safety process will determine whether drug safety actually improves. Propping up the Office of Drug Safety with more bureaucratic prominence or adding new requirements to the preapproval process will add to the cost of drug development and not make drugs safer. New information tools can dramatically improve postmarketing surveillance and collection of data on safety. This information could then be used to reach more definitive regulatory conclusions sooner. New incentives will be needed to entice payers and product developers to work on building a broader, more robust system for collecting data on drug safety.Keywords
This publication has 7 references indexed in Scilit:
- A Clinical Research Strategy To Support Shared Decision MakingHealth Affairs, 2005
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindNew England Journal of Medicine, 2004
- Antidepressants and the Risk of Suicidal BehaviorsJAMA, 2004
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- The Costs of Conducting Clinical ResearchJournal of Clinical Oncology, 2003
- Is the FDA approving drugs too fast?BMJ, 1998
- Time to Act on Drug SafetyJAMA, 1998